Pharmaceutical Commercialization Services: Market Dynamics
|There is strong demand for pharmaceutical commercialization services, especially given the heightened importance of value demonstration and communication for the commercial success of approved therapeutics, vaccines, and diagnostics, coupled with continued outsourcing by life science sponsors of historically core functions, and a marked uptick in FDA approvals of novel therapeutics, including NMEs, BLAs, mAbs, and cell and gene therapies, over the past few years. In addition, more than 65% of the innovation in the industry is occurring outside of the four walls of big pharma, with more mid-sized, small, and emerging biopharmaceutical companies working to commercialize novel products, for which a greater degree of outsourced support is typically required. There is compelling rationale to outsource to dedicated high-quality commercialization services players due to the following elements:
Read more about our key perspectives on the market dynamics, growth drivers, and valuation considerations, including recent precedent M&A transactions, as well as selected Edgemont case studies.